ASCO Conference Coverage

Immunotherapies Can Kill Money Bonuses in OC Model

(Medscape Medical News) June 13, 2019 - The federal government's Oncology Care Model (OCM) is based on the idea that you can motivate clinicians with cash rewards to improve care and reduce costs.

read article (free registration required)

Cancer Patients School Clinicians About Marijuana

(Medscape Medical News) June 10, 2019 - Ashley Glode, PharmD, a pharmacist in the gastrointestinal clinic at the University of Colorado Cancer Center, Anshutz, says marijuana is not a taboo topic in her state, where medical use was approved in 2000 and recreational use in 2012.

read article (free registration required)

Oncternal Therapeutics Goes Public After Reverse Merger With GTx

(Xconomy San Diego) June 12, 2019 - Oncternal Therapeutics has joined the growing ranks of San Diego biotechs to go public, but it didn’t go through an IPO to get there.

read article

Oncologists Are Engaging Less With Industry Since Open Payments

(Medscape Medical News) June 7, 2019 - Since the inception of the Open Payments program, fewer American medical oncologists appear to be engaging with industry, new findings show.

read article (free registration required)

Biotechs Dive Deeper Into Targeted Cancer Research, Despite Costs

(BioPharma Dive) June 5, 2019 - An AstraZeneca cancer drug works best in people with an uncommon mutation. For a recent study evaluating whether the drug offered benefits to pancreatic cancer who have the mutation, researchers screened more than 3,300 patients. Only 247 of them tested positive, and even fewer participated in the study.

read article

ASCO 2019: Test All Triple Negative Breast Cancer Patients for PD-L1

(Physician’s Weekly) June 5, 2019 - One of the repeated themes of the American Society of Clinical Oncology meeting here was the need for baseline testing of any target that can inform truly precision use of targeted therapies.

read article

Men with Early-Stage Prostate Cancer Who Choose Active Surveillance Often Don’t Follow Monitoring Guidelines

(UNC LCCC) June 2, 2019 - Preliminary results from a University of North Carolina Lineberger Comprehensive Cancer Center study found that just 15 percent of a group of men in North Carolina with early-stage prostate cancer who choose active surveillance instead of treatment followed the recommended monitoring guidelines.

read article

Opinion: Iovance and Amgen Are Making Cancer History

(Washington Post/Bloomberg) June 5, 2019 - The annual meeting of the American Society of Clinical Oncology (ASCO), which wrapped up Tuesday, is one of the drug industry’s most prominent platforms for showcasing promising cancer research and treatments. This year was no exception.

read article (free registration required)

Amgen's Trastuzumab Biosimilar, Kanjinti, Clinically Similar to Herceptin in Cardiac Safety

(The Center For Biosimilars) June 6, 2019 - During this week’s 2019 American Society of Clinical Oncology Annual Meeting, researchers reported on the cardiac safety of Amgen’s biosimilar trastuzumab, ABP 980 (approved in the European Union under the name Kanjinti), versus the reference trastuzumab, Herceptin.

read article

ASCO 2019: Breast Cancer Drug Effective In 80 Per Cent Of Men With BRCA-Mutant Prostate Cancer

[ICR [UK]) June 5, 2019 - A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports. Some 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA breast cancer genes responded to olaparib. And even though men in the trial had advanced, heavily pre-treated prostate cancer, olaparib delayed progression of the disease in these patients for a median of 8.3 months, with 35 per cent free of progression for more than a year.

read article

'Unprecedented' Survival Benefit Vanishes in Confirmatory Cancer Trial

(MedPage Today) June 3, 2019 - A year-long overall survival (OS) improvement with olaratumab (Lartruvo) in an early-phase soft-tissue sarcoma trial disappeared when the drug was tested in a larger phase III trial. Among more than 500 doxorubicin-treated patients in ANNOUNCE, those randomized to olaratumab had a median OS of 20.4 months compared with 19.7 months for those on placebo (HR 1.05, 95% CI 0.84-1.30, P=0.69), reported William D. Tap, MD, of Memorial Sloan Kettering Cancer Center in New York City.

read article (free registration required)

AKT Inhibitor Doubles PFS in Advanced Breast Cancer

(MedPage Today) June 4, 2019 - Early randomized trial of capivasertib shows promise in ER-positive disease.

read article (free registration required)

RemeGen, Ltd. Announces Positive Results from RC48 Clinical Trial in HER2-Positive Metastatic or Unresectable Urothelial Cancer

(BioSpace) June 4, 2019 - Results, presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrated clinically meaningful response in patients with urothelial carcinoma whose treatment previously failed, a population with high unmet medical need.

read article

TG Therapeutics Presents Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting

(Yahoo! Finance) June 4, 2019 - TG Therapeutics, Inc. today presented positive interim data from the ongoing single-arm marginal zone lymphoma (MZL) cohort of its Phase 2b UNITY-NHL trial currently evaluating umbralisib as a single agent in patients with relapsed/refractory MZL.

read article

Innovent Provides Update on the Results of Sintilimab for the Treatment of Extranodal NK/T Cell Lymphoma by Oral Presentation at ASCO

(Yahoo! Finance) June 4, 2019 - Innovent Biologics, Inc. today announced that the research data on the treatment of relapsed or refractory extranodal NK/T cell lymphoma (ORIENT-4) by sintilimab, the anti-PD-1 antibody that co-developed with Eli Lilly and Company, was presented in an oral session at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) [Abstract #7504; Tuesday, June 4, 10:57 AM -11:09 AM CDT].

read article

Eisai Announces Additional Data from Ongoing Phase 1 Trial of Investigational Combination of HALAVEN® (eribulin mesylate) with Polyphor's CXCR4 Antagonist Balixafortide in HER2-Negative Metastatic Breast Cancer at ASCO 2019

(Markets Insider) June 4, 2019 - Eisai today announced additional data from an ongoing Phase 1 trial exploring the investigational combination of eribulin and balixafortide, a CXCR4 antagonist, in patients with HER2-negative metastatic breast cancer (Abstract #2606), were presented at the 2019 ASCO Annual Meeting in Chicago from May 31-June 4.

read article

ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More

(Xconomy National) June 5, 2019 - The American Society of Clinical Oncology meeting in Chicago has wrapped up for another year.

read article

ASCO Updates: RemeGen, Genentech, Johnson & Johnson, Bristol-Myers Squibb and Bayer

(BioSpace) June 4, 2019 - As the American Society of Clinical Oncology (ASCO) Annual Meeting winds down, here’s a look at some of Monday’s top stories.

read article

ASCO 2019: Immunotherapy Better Than Aggressive Chemotherapy As First Treatment Option For Recurrent Head And Neck Cancer

(ICR [UK]) June 4, 2019 - Immunotherapy used with chemotherapy or on its own is a better first-line treatment for people with head and neck cancer that has returned than standard aggressive chemotherapy, new clinical trial results show. At diagnosis, people with head and neck cancer that has come back or spread are currently given an ‘extreme’ cocktail of two chemotherapy drugs and a targeted antibody treatment.

read article

At ASCO, Targeted Lung Cancer Drugs Shrink Tumors Caused By Rare Genetic Mutations

(STAT Plus) June 3, 2019 - Precision medicine in lung cancer is making a big impact at this year’s ASCO meeting. Rare mutations in lung tumors discovered through genetic screening are leading to the development of highly targeted drugs. And these drugs are shrinking tumors in patients not helped by current treatments. Two case studies: A drug called BLU-667 from the biotech Blueprint Medicines caused tumors to shrink in 60% of patients with lung tumors containing an alteration to a gene called RET. These patients entered the clinical trial after standard chemotherapy stopped working.

read article (paid subscription required)
Next Page